

**ESKIN CLINICAL TRIAL UNITS SHIPPED TO THE USA**

OBJ Limited (ASX:OBJ) is pleased to announce that it has manufactured and shipped the first clinical trial eSkin™ units to its partner's Contract Research Organization (CRO) in the USA. The shipment is part of the Exclusive Collaboration Agreement involving the Company's proprietary eSkin™ technology, announced to the market on 25<sup>th</sup> February 2013. The clinical trial units were developed by the Company in consultation with its partner's scientific teams in the USA and Europe and will be evaluated in an independent clinical efficacy study in the USA.



The clinical trial will serve to prove up efficacy in humans for marketing claims and, subject to success in the clinical trial, as a pre-cursor to potential licensing, supply and global distribution.

eSkin™ incorporates OBJ's patented Dermaportation powered transdermal delivery technology that has been shown to enhance the delivery of key anti-aging and skincare ingredients deeper and more effectively into the skin.

The clinical trial is designed to demonstrate consumer perceivable levels of performance improvement including more rapid reduction of fine lines and wrinkles in comparison with the commercial formulation applied by hand. The use of an independent CRO validates the data generated to then be potentially used commercially throughout the world.

If successful the clinical trial will be a major step forward for the Company in the potential commercial development of its powered drug delivery technology and its web-enabled personalisation capabilities that allow eSkin™ to optimise cosmetic delivery precisely to individual needs via the world wide web using portable devices.

For more information:


Mr Glyn Denison	Director	<b>Telephone</b>	+618 9443 3011
		<b>Email</b>	<a href="mailto:info@obj.com.au">info@obj.com.au</a>
		<b>Web</b>	<a href="http://www.obj.com.au">www.obj.com.au</a>

- ENDS -

For personal use only

# OBJ Limited

leaders in magnetic micro-array drug delivery



## **About OBJ:**

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

## **About OBJ's Technologies**

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

## **Forward-looking Statements**

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

---

ABN 72 056 482 636

284 Oxford Street, Leederville 6007 Perth, Western Australia

Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960

[www.obj.com.au](http://www.obj.com.au)

For personal use only